Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism

doi:10.12092/j.issn.1009-2501.2021.07.017

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (7): 836-840.doi: 10.12092/j.issn.1009-2501.2021.07.017

Previous Articles Next Articles

Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism

YANG Hechun, SHI Daohua

Department of Pharmacy, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou 350001, Fujian, China

Received:2021-04-21 Revised:2021-07-03 Online:2021-07-26 Published:2021-08-09

Abstract

Abstract: Tumor drug resistance is currently one of the most difficult clinical problems. There are many theories on the mechanism of tumor drug resistance, and metabolic reprogramming is one of its mechanisms. Tumor cells undergo metabolic reprogramming to meet the energy requirements of proliferation, especially the changes in the glucose metabolism. This article reviews the glucose metabolism reprogramming-related enzymes and the associated small molecule inhibitors that reverse tumor drug resistance.

Key words: metabolic reprogramming, Warburg effect, drug resistance, glucose metabolism, small molecule inhibitors

CLC Number:

YANG Hechun, SHI Daohua . Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.

[1]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[2]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[3]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[4]	WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
[5]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[6]	WEI Songchang, YANG Hongqi, ZHANG Hongjuan, SHI Xiaoli, REN Kaiwen. Correlation between the expression of RON protein and CXC chemokine receptor 4 protein and abiraterone resistance in patients with castration-resistant prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 414-422.
[7]	JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing. Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
[8]	WANG Ziyuan, SUN Mingyu. Advances in research on long non-coding RNA in drug resistance of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
[9]	YANG Yanlang, LI Yan, WANG Lin. Distribution and drug resistance of bacterial pathogens in the infecting inpatients of department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 203-208.
[10]	XU Weiping, ZHOU Weiying. Advances in the sensitization mechanism of chemotherapeutic drugs for bladder cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1060-1064.
[11]	ZHAO Qiaosu，YE Hua，SUN Qinxue. Effects of circadian clock gene Period2 on Warburg effect and metastasis in hepatocellular carcinoma cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1134-1141.
[12]	WANG Xiaoli, LU Shuping, DAI Jiale. Role of MSX2 in melanoma cells for trametinib resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1147-1154.
[13]	FU Peishu, SUN Fengjun, FENG Wei, XIONG Lirong, LI Xiaoyu, XIA Peiyuan. Progress in drug therapy for multidrug-resistant Acinetobacter baumannii infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1181-1187.
[14]	WANG Jin, YANG Yi, GUO Li, LI Wenyan, RUAN Shuiliang. Probucol inhibited metastasis and invasion by reversing Warburg effect and regulated reprogramming of hepatoma cell HepG2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 601-607.
[15]	SHAO Junjin, LI Ya, LV Lei, WU Kaihua. Effects of dexmedetomidine and hydroxyethyl starch combined with fentanyl on brain glucose and oxygen metabolism in elderly patients with hypertensive cerebral hemorrhage after emergency surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 688-693.

Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments